This is the first time the long-term client has requested a preclinical dissolution study from ISAB, having previously carried out such studies using in-house technology. The new study will use DissolvIt® - ISAB's unique, highly sensitive dissolution testing technology that generates high-precision data in the preclinical phase that can accurately predict how inhaled substances will perform in the clinical phase, reducing attrition, risk and costs.

DissolvIt® is being evaluated in an FDA BAA (Broad Agency Announcement) contract research project and it was also presented by ISAB CSO Per Gerde at an FDA GDUFA (Generic Drug User Fee Amendments) webinar on May 20th 2024 to a large audience of specialist industry professionals.

ISAB CEO Manoush Masarrat: "we are very pleased that such an important customer is choosing DissolvIt® for the first time to carry out dissolution testing. Preclinical dissolution testing is gaining traction industry-wide and DissolvIt® is a leader in this field. This is an exciting step and has significant potential to lead to further DissolvIt® studies in the near future".

Discover DissolvIt[®]

Read ISAB's publications on DissolvIt[®]here. (https://www.inhalation.se/publications/)

Discover DissolvIt's in vitro capabilities here. (https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/)

Explore Inhalation Research Services here (https://www.inhalation.se/inhalation-research-services/).